Show simple item record

dc.contributor.authorGhalamfarsa, G
dc.contributor.authorHojjat-Farsangi, M
dc.contributor.authorMohammadnia-Afrouzi, M
dc.contributor.authorAnvari, E
dc.contributor.authorFarhadi, S
dc.contributor.authorYousefi, M
dc.contributor.authorJadidi-Niaragh, F
dc.date.accessioned2018-08-26T08:35:06Z
dc.date.available2018-08-26T08:35:06Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/52617
dc.description.abstractMultiple sclerosis (MS) is an autoimmune neurodegenerative disease characterized with immunopathobiological events, including lymphocytic infiltration into the central nervous system (CNS), microglia activation, demyelination and axonal degeneration. Although several neuroprotective drugs have been designed for the treatment of MS, complete remission is yet matter of debate. Therefore, development of novel therapeutic approaches for MS is of a high priority in immunological research. Nanomedicine is a recently developed novel medical field, which is applicable in both diagnosis and treatment of several cancers and autoimmune diseases. Although there is a marked progress in neuroimaging through using nanoparticles, little is known regarding the therapeutic potential of nanomedicine in neurological disorders, particularly MS. Moreover, the majority of data is limited to the MS related animal models. In this review, we will discuss about the brain targeting potential of different nanoparticles as well as the role of nanomedicine in the diagnosis and treatment of MS and its animal model, experimental autoimmune encephalomyelitis. é 2016 Informa UK Limited trading as Taylor & Francis Group.
dc.language.isoEnglish
dc.relation.ispartofJournal of Immunotoxicology
dc.subjectcarbon nanoparticle
dc.subjectdendrimer
dc.subjectliposome
dc.subjectnanocapsule
dc.subjectnanosphere
dc.subjectsolid lipid nanoparticle
dc.subjectnanoparticle
dc.subjectneuroprotective agent
dc.subjectblood brain barrier
dc.subjectcentral nervous system
dc.subjectdrug delivery system
dc.subjectexperimental autoimmune encephalomyelitis
dc.subjectgel
dc.subjectmicelle
dc.subjectmultiple sclerosis
dc.subjectnanoemulsion
dc.subjectnonhuman
dc.subjectpolymerization
dc.subjectpriority journal
dc.subjectReview
dc.subjecttheranostic nanomedicine
dc.subjectanimal
dc.subjectblood brain barrier
dc.subjectdiagnostic imaging
dc.subjectdisease model
dc.subjectdrug effects
dc.subjectEncephalomyelitis, Autoimmune, Experimental
dc.subjecthuman
dc.subjectmouse
dc.subjectmultiple sclerosis
dc.subjectneurogenic inflammation
dc.subjectutilization
dc.subjectAnimals
dc.subjectBlood-Brain Barrier
dc.subjectDiagnostic Imaging
dc.subjectDisease Models, Animal
dc.subjectEncephalomyelitis, Autoimmune, Experimental
dc.subjectHumans
dc.subjectMice
dc.subjectMultiple Sclerosis
dc.subjectNanoparticles
dc.subjectNeurogenic Inflammation
dc.subjectNeuroprotective Agents
dc.subjectTheranostic Nanomedicine
dc.titleApplication of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis
dc.typeArticle
dc.citation.volume13
dc.citation.issue5
dc.citation.spage603
dc.citation.epage619
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.3109/1547691X.2016.1159264


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record